Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Lexicon Pharmaceuticals Inc LXRX
$2.31
▼ -1.28%
($-0.03)
📅 Earnings This Week
Open
$2.32
Prev Close
$2.34
Day Range
$2.25 – $2.35
52W Range
$1.01 – $2.68
Market Cap
$1.03B
Beta
1.03
EPS (TTM)
$-0.07
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2000-04-07 |
| Shares Out. | 444,200,000 |
| Website | lexpharma.com/ ↗ |
| Phone | 12818633000 |
| Employees | 81 |
| Revenue | $21.1M |
| Gross Profit | $21.0M |
| Net Income | -$1.0M |
| Total Assets | $268.8M |
| Total Liabilities | $66.0M |
| Equity | $202.9M |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Lexicon Pharmaceuticals Inc is a publicly traded company under the ticker symbol LXRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)
📰 Latest News for LXRX
Lexicon Pharmaceuticals (LXRX) As Phase 3 Enrollment Beats Plan Faces An Undervalued View
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical Trial